136 related articles for article (PubMed ID: 9835904)
1. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
Ewer MS; Jaffe N; Ried H; Zietz HA; Benjamin RS
Med Pediatr Oncol; 1998 Dec; 31(6):512-5. PubMed ID: 9835904
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
[TBL] [Abstract][Full Text] [Related]
3. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
Gillings S; Johnson J; Fulmer A; Hauck M
Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity.
Lum BL; Svec JM; Torti FM
Drug Intell Clin Pharm; 1985 Apr; 19(4):259-64. PubMed ID: 3891276
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
7. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
8. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
[TBL] [Abstract][Full Text] [Related]
9. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
[TBL] [Abstract][Full Text] [Related]
12. Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt GA; Dorup I; Sorensen K; Sullivan I
Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.
Bielack SS; Erttmann R; Winkler K; Landbeck G
Eur J Cancer Clin Oncol; 1989 May; 25(5):873-82. PubMed ID: 2661240
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.
Hayakawa H; Komada Y; Hirayama M; Hori H; Ito M; Sakurai M
Med Pediatr Oncol; 2001 Jul; 37(1):4-9. PubMed ID: 11466716
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin.
Hallman BE; Hauck ML; Williams LE; Hess PR; Suter SE
J Vet Intern Med; 2019 Mar; 33(2):783-791. PubMed ID: 30697816
[TBL] [Abstract][Full Text] [Related]
18. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
Soker M; Kervancioglu M
Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
[TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
